Brian E. Lewis MD, MPH, FACP
Assistant Professor of Clinical Medicine, Department of Hematology and Medical Oncology, Tulane University School of Medicine, New Orleans, LouisianaBiographical Sketch:
Dr. Brian Lewis is an Assistant Professor of Clinical Medicine in the Department of Hematology and Medical Oncology at Tulane University School of Medicine in New Orleans. He is also the Chair of the Fellowship Advancement Committee of the Hematology and Medical Oncology Fellowship Program at Tulane.
Following his graduation from George Mason University in Fairfax, Virginia, Dr. Lewis enrolled in the Tulane University School of Public Health and, upon completing his MPH degree, entered medical school at Tulane. He completed his medical degree and residency training in internal medicine at Tulane, where he also completed his fellowship in hematology and medical oncology.
Dr. Lewis is a member of several professional societies, including the American Society of Hematology and the American Society of Clinical Oncology. Dr. Lewis is a Fellow of the American College of Physicians.
Positions:
Assistant Professor of Clinical Medicine, Department of Hematology and Medical Oncology; Chair, Fellowship Advancement Committee, Hematology and Medical Oncology Fellowship Program, Tulane University School of Medicine
Degrees:
MPH: Tulane University School of Public Health, New Orleans, Louisiana
MD: Tulane University School of Medicine
Disclosures
Dr. Brian Lewis does not have any financial interests to disclose.
Recent Contributions to PracticeUpdate:
- ADT No Longer the Standard of Care for Metastatic Prostate Cancer: An Expert Roundtable
- ESMO 2017: Recommendations From Dr. Brian Lewis
- Reduced-Dose Cabazitaxel vs the Currently Approved Dose in Post-Docetaxel Patients With Metastatic Castration-Resistant Prostate Cancer
- Cabazitaxel Not Superior to Docetaxel as First-Line Therapy in Metastatic Castration-Resistant Prostate Cancer
- ASCO 2017: Abstract Recommendations From Dr. Brian Lewis—Prostate Cancer
- Abiraterone Acetate for Metastatic Prostate Cancer Patients With Suboptimal Response to Hormone Induction
- 2016 Top Stories in Advanced Prostate Cancer: Germline DNA-Repair Mutations in Metastatic Disease
- Apalutamide Safe and Effective in Treatment of High-Risk Nonmetastatic Castration-Resistant Prostate Cancer
- Outcomes Following Adjuvant Radiotherapy in Lymph Node–Positive Prostate Cancer
- Genomic Classifier Shows Promise for Predicting Metastasis After Salvage Radiation for Prostate Cancer